| Year |
Citation |
Score |
| 2023 |
Pei PP, Fitzmaurice KP, Le MH, Panella C, Jones ML, Pandya A, Horsburgh CR, Freedberg KA, Weinstein MC, Paltiel AD, Reddy KP. The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis. Mdm Policy & Practice. 8: 23814683231198873. PMID 37743931 DOI: 10.1177/23814683231198873 |
0.417 |
|
| 2022 |
Pandya A, Paulden M, Zhu J, Lavelle TA, Hammitt J. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X221097106. PMID 35531945 DOI: 10.1177/0272989X221097106 |
0.653 |
|
| 2021 |
Zang X, Mah C, Linh Quan AM, Min JE, Armstrong WS, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Kirk GD, Marshall BD, Mehta SH, Metsch LR, Pandya A, Schackman BR, et al. Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum: A contrast of six US cities. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 34723929 DOI: 10.1097/QAI.0000000000002844 |
0.47 |
|
| 2021 |
Quan AML, Mah C, Krebs E, Zang X, Chen S, Althoff K, Armstrong W, Behrends CN, Dombrowski JC, Enns E, Feaster DJ, Gebo KA, Goedel WC, Golden M, Marshall BDL, ... ... Pandya A, et al. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. The Lancet. Hiv. PMID 34370977 DOI: 10.1016/S2352-3018(21)00147-8 |
0.544 |
|
| 2020 |
Krebs E, Zang X, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, Strathdee SA, et al. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. The Journal of Infectious Diseases. 222: S301-S311. PMID 32877548 DOI: 10.1093/Infdis/Jiaa130 |
0.544 |
|
| 2020 |
Nosyk B, Weiner J, Krebs E, Zang X, Enns B, Behrends CN, Feaster DJ, Jalal H, Marshall BDL, Pandya A, Schackman BR, Meisel ZF. Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X20945308. PMID 32755285 DOI: 10.1177/0272989X20945308 |
0.481 |
|
| 2020 |
Pandya A, Soeteman DI, Gupta A, Kamel H, Mushlin AI, Rosenthal MB. Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework? Circulation. Cardiovascular Quality and Outcomes. 13: e006492. PMID 32615799 DOI: 10.1161/Circoutcomes.120.006492 |
0.384 |
|
| 2020 |
Nosyk B, Krebs E, Zang X, Piske M, Enns B, Min JE, Behrends CN, Del Rio C, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Meisel ZF, Metsch LR, Pandya A, et al. 'Ending the Epidemic' will not happen without addressing racial/ethnic disparities in the US HIV epidemic. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32424416 DOI: 10.1093/Cid/Ciaa566 |
0.512 |
|
| 2020 |
Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Mentz RJ, O'Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. Jama Cardiology. PMID 32401264 DOI: 10.1001/Jamacardio.2020.1240 |
0.32 |
|
| 2020 |
Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, et al. Ending the HIV epidemic in the USA: an economic modelling study in six cities. The Lancet. Hiv. PMID 32145760 DOI: 10.1016/S2352-3018(20)30033-3 |
0.524 |
|
| 2020 |
Mason SE, Zhu J, Rahaghi FN, Washko GR, Pandya A. Cost-effectiveness microsimulation of catheter-directed thrombolysis in submassive pulmonary embolism using a right ventricular function model. Journal of Thrombosis and Thrombolysis. PMID 32048167 DOI: 10.1007/S11239-020-02058-Y |
0.373 |
|
| 2019 |
Choi SE, Sima C, Pandya A. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes. Diabetes Care. PMID 31882408 DOI: 10.2337/Dc19-1201 |
0.336 |
|
| 2019 |
Zang X, Krebs E, Min JE, Pandya A, Marshall BDL, Schackman BR, Behrends CN, Feaster DJ, Nosyk B. Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X19889356. PMID 31865849 DOI: 10.1177/0272989X19889356 |
0.536 |
|
| 2019 |
Baradaran H, Gupta A, Anzai Y, Mushlin AI, Kamel H, Pandya A. Cost Effectiveness of Assessing Ultrasound Plaque Characteristics to Risk Stratify Asymptomatic Patients With Carotid Stenosis. Journal of the American Heart Association. 8: e012739. PMID 31645165 DOI: 10.1161/Jaha.119.012739 |
0.406 |
|
| 2019 |
Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, Weinstein MC. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. American Heart Journal. 214: 77-87. PMID 31174054 DOI: 10.1016/J.Ahj.2019.04.020 |
0.526 |
|
| 2019 |
Baradaran H, Mushlin A, Kamel H, Gupta A, Pandya A. Abstract WP404: Cost-Effectiveness of Plaque Echolucency on Ultrasound as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis Stroke. 50. DOI: 10.1161/Str.50.Suppl_1.Wp404 |
0.353 |
|
| 2018 |
Pandya A, Asch DA, Volpp KG, Sy S, Troxel AB, Zhu J, Weinstein MC, Rosenthal MB, Gaziano TA. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. Jama Network Open. 1: e182008. PMID 30646152 DOI: 10.1001/jamanetworkopen.2018.2008 |
0.439 |
|
| 2018 |
Pandya A. Improving Health Care Value by Considering Cost-effectiveness-Reply. Jama. 320: 1287-1288. PMID 30264111 DOI: 10.1001/Jama.2018.10624 |
0.341 |
|
| 2018 |
Pandya A, Doran T, Zhu J, Walker S, Arntson E, Ryan AM. Modelling the cost-effectiveness of pay-for-performance in primary care in the UK. Bmc Medicine. 16: 135. PMID 30153827 DOI: 10.1186/S12916-018-1126-3 |
0.393 |
|
| 2018 |
Pandya A. Adding Cost-effectiveness to Define Low-Value Care. Jama. PMID 29710341 DOI: 10.1001/Jama.2018.2856 |
0.318 |
|
| 2018 |
Pandya A. Statins and the Classic Decision Analysis: Treat, Test, or Neither? Circulation. Cardiovascular Quality and Outcomes. 11: e004688. PMID 29650718 DOI: 10.1161/Circoutcomes.118.004688 |
0.376 |
|
| 2017 |
Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease Policy Micro-Simulation Model using Both Survival and Receiver Operating Characteristic Curves. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X17706081. PMID 28490271 DOI: 10.1177/0272989X17706081 |
0.536 |
|
| 2016 |
Gaziano TA, Abrahams-Gessel S, Alam S, Alam D, Ali M, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gutierrez L, Irazola V, Levitt NS, Miranda JJ, Bernabe-Ortiz A, Pandya A, Rubinstein A, et al. Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations. Global Heart. 11: 37-46.e2. PMID 27102021 DOI: 10.1016/J.Gheart.2015.12.003 |
0.346 |
|
| 2016 |
Pandya A, Eggman AA, Kamel H, Gupta A, Schackman BR, Sanelli PC. Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. Plos One. 11: e0148106. PMID 26840397 DOI: 10.1371/Journal.Pone.0148106 |
0.537 |
|
| 2015 |
Pandya A, Weinstein MC, Gaziano TA. Cost-effectiveness of Statin Therapy for ASCVD--Reply. Jama. 314: 2191-2. PMID 26599190 DOI: 10.1001/Jama.2015.12928 |
0.522 |
|
| 2015 |
Gaziano T, Cho S, Sy S, Pandya A, Levitt NS, Steyn K. Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa. Health Affairs (Project Hope). 34: 1578-85. PMID 26355061 DOI: 10.1377/Hlthaff.2015.0351 |
0.372 |
|
| 2015 |
Gaziano T, Abrahams-Gessel S, Surka S, Sy S, Pandya A, Denman CA, Mendoza C, Puoane T, Levitt NS. Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. Health Affairs (Project Hope). 34: 1538-45. PMID 26355056 DOI: 10.1377/Hlthaff.2015.0349 |
0.351 |
|
| 2015 |
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. Jama. 314: 142-50. PMID 26172894 DOI: 10.1001/Jama.2015.6822 |
0.524 |
|
| 2015 |
Gupta A, Mushlin AI, Kamel H, Navi BB, Pandya A. Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis. Radiology. 277: 763-72. PMID 26098459 DOI: 10.1148/Radiol.2015142843 |
0.342 |
|
| 2015 |
Pandya A, Gupta A, Kamel H, Navi BB, Sanelli PC, Schackman BR. Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients. Radiology. 274: 455-63. PMID 25225841 DOI: 10.1148/Radiol.14140501 |
0.595 |
|
| 2014 |
Deaño RC, Pandya A, Jones EC, Borden WB. A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. Current Atherosclerosis Reports. 16: 438. PMID 25052768 DOI: 10.1007/S11883-014-0438-9 |
0.397 |
|
| 2014 |
Pandya A, Weinstein MC, Salomon JA, Cutler D, Gaziano TA. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circulation. Cardiovascular Quality and Outcomes. 7: 25-32. PMID 24425701 DOI: 10.1161/Circoutcomes.113.000397 |
0.531 |
|
| 2014 |
Simon MS, Leff JA, Pandya A, Cushing M, Shaz BH, Calfee DP, Schackman BR, Mushlin AI. Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. Transfusion. 54: 889-99. PMID 24252132 DOI: 10.1111/Trf.12492 |
0.517 |
|
| 2013 |
Pandya A, Gaziano TA, Weinstein MC, Cutler D. More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Affairs (Project Hope). 32: 1706-14. PMID 24101059 DOI: 10.1377/Hlthaff.2013.0449 |
0.504 |
|
| 2012 |
O'Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA, Perfect JR, Papadopoulos G. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 69: 149-56. PMID 22215361 DOI: 10.2146/Ajhp110149 |
0.508 |
|
| 2011 |
Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC. Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 14: 700-4. PMID 21839408 DOI: 10.1016/J.Jval.2011.01.002 |
0.438 |
|
| 2011 |
Pandya A, Weinstein MC, Gaziano TA. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. Plos One. 6: e20416. PMID 21655241 DOI: 10.1371/Journal.Pone.0020416 |
0.482 |
|
| 2010 |
Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 28: 995-1000. PMID 20936883 DOI: 10.2165/11538660-000000000-00000 |
0.457 |
|
| 2010 |
Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, Waters DD, Drummond M, Weinstein MC. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 28: 47-60. PMID 20014876 DOI: 10.2165/11531440-000000000-00000 |
0.477 |
|
| 2009 |
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 666-73. PMID 19508661 DOI: 10.1111/J.1524-4733.2008.00486.X |
0.518 |
|
| 2009 |
Taylor DC, Pandya A, Thompson D, Chu P, Graff J, Shepherd J, Wenger N, Greten H, Carmena R, Drummond M, Weinstein MC. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 10: 255-65. PMID 18800232 DOI: 10.1007/S10198-008-0126-1 |
0.526 |
|
| 2008 |
Rosen V, Taylor D, Parekh H, Pandya A, Thompson D, Kuznik A, Waters D, Drummond M, Weinstein M. Cost-Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure in the US Journal of Cardiac Failure. 14: S81. DOI: 10.1016/J.Cardfail.2008.06.446 |
0.502 |
|
| 2007 |
O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US. Blood. 110: 3336-3336. DOI: 10.1182/Blood.V110.11.3336.3336 |
0.561 |
|
| 2007 |
Taylor D, Pandya A, Thompson D, Chu P, Graff J, LaRosa J, Grundy S, Shepherd J, Wenger N, Drummond M. PO16-439 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY Atherosclerosis Supplements. 8: 125. DOI: 10.1016/S1567-5688(07)71449-6 |
0.383 |
|
| 2007 |
Taylor D, Kruzikas D, Pandya A, Iskandar R, Gilmore K, Weinstein M. MC1 METHODS OF MODEL CALIBRATION:A COMPARATIVE APPROACH Value in Health. 10: A7. DOI: 10.1016/S1098-3015(10)68554-3 |
0.431 |
|
| 2006 |
O’Sullivan AK, Pandya A, Thompson D, Papadopoulos G, Weinstein MC, Perfect JR, Langston A. Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S. Blood. 108: 3311-3311. DOI: 10.1182/Blood.V108.11.3311.3311 |
0.57 |
|
| 2006 |
Taylor DCA, Pandya A, Thompson D, Chu P, Graff J, Drummond M, Larosa JC, Grundy SM, Shepherd J, Wenger NK. Mo-P5:344 Cost-effectiveness of intensive lipid-lowering treatment with atorvastatin 80MG versus 10MG in secondary cardiovascular prevention in the UK Atherosclerosis Supplements. 7: 121. DOI: 10.1016/S1567-5688(06)80475-7 |
0.325 |
|
| 2006 |
Taylor D, Pandya A, Thompson D, Chu P, Graff J, LaRosa J, Grundy S, Wenger N, Shepherd J, Drummond M. PCV28 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY Value in Health. 9: A345. DOI: 10.1016/S1098-3015(10)63644-3 |
0.382 |
|
| Show low-probability matches. |